Prospera Financial Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $482K | Buy |
3,835
+1,158
| +43% | +$146K | 0.01% | 920 |
|
|
2025
Q1 | $296K | Buy |
2,677
+86
| +3% | +$9.51K | 0.01% | 992 |
|
|
2024
Q4 | $354K | Buy |
2,591
+9
| +0.3% | +$1.23K | 0.01% | 867 |
|
|
2024
Q3 | $297K | Sell |
2,582
-24
| -0.9% | -$2.77K | 0.01% | 924 |
|
|
2024
Q2 | $359K | Sell |
2,606
-333
| -11% | -$45.8K | 0.01% | 842 |
|
|
2024
Q1 | $405K | Buy |
2,939
+100
| +4% | +$13.8K | 0.01% | 776 |
|
|
2023
Q4 | $374K | Sell |
2,839
-85
| -3% | -$11.2K | 0.01% | 754 |
|
|
2023
Q3 | $329K | Sell |
2,924
-73
| -2% | -$8.21K | 0.01% | 769 |
|
|
2023
Q2 | $283K | Buy |
+2,997
| New | +$283K | 0.01% | 823 |
|
|
2022
Q2 | – | Sell |
-496
| Closed | -$46K | – | 2248 |
|
|
2022
Q1 | $46K | Buy |
+496
| New | +$46K | ﹤0.01% | 1413 |
|
|
2021
Q3 | – | Sell |
-12,679
| Closed | -$1.23M | – | 834 |
|
|
2021
Q2 | $1.23M | Buy |
+12,679
| New | +$1.23M | 0.06% | 336 |
|
|
2020
Q4 | – | Sell |
-10
| Closed | -$1K | – | 1247 |
|
|
2020
Q3 | $1K | Buy |
+10
| New | +$1K | ﹤0.01% | 1557 |
|